Quantcast
Last updated on April 17, 2014 at 11:00 EDT

Latest Sanofi Stories

2013-05-16 12:29:49

CHICAGO, May 16, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Genomic Health Inc. (Nasdaq:GHDX), Sanofi (NYSE:SNY), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN), Amgen Inc. (Nasdaq:AMGN) and Isis Pharmaceuticals, Inc. (Nasdaq:ISIS). (Logo:...

2013-05-14 23:31:32

Emergency room visits attributed to sleep aids have increased nearly 220% in recent years, and treatment providers are trying to find solutions to address this growing problem. Malibu, CA (PRWEB) May 14, 2013 According to a recent article in USA Today, the number of emergency room visits attributed to sleep-inducing drugs (particularly Zolpidem, the active ingredient in Ambien) has risen drastically in both numerical scope and severity. According to a report by the Substance Abuse and...

2013-05-15 00:21:05

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled...

2013-05-06 23:03:40

Studies conducted on the blood-thinning drug Plavix indicate no benefit when taken with aspirin and may increase changes of suffering a stroke. The Law Firm of d'Oliveira & Associates wishes to inform the general public that with Plavix going generic, cases of side effects associated with the drug may increase. (PRWEB) May 06, 2013 Marketed by Bristol-Myers Squibb and Sanofi Pharmaceuticals and currently the second most commonly prescribed drug on the U.S. market, Plavix is used to...

2013-05-06 08:26:11

-Donation to Diabetes Hands Foundation Doubled When Documentary Reaches 10,000 Views- BRIDGEWATER, N.J., May 6, 2013 /PRNewswire/ -- Sanofi US and Golden Globe and Emmy nominated actress Elizabeth Perkins proudly premiered the Diabetes Co-Stars documentary, "Strength in Numbers," at the American Diabetes Association Expo in Los Angeles, CA this past weekend. The film, produced by Elizabeth and her 'co-star' and husband Julio Macat, features her diabetes story as well as two other...

2013-05-03 08:25:00

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi. Regeneron acquired full rights to antibodies targeting the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications...

2013-05-02 08:36:08

Growth platforms(2) sales increased 8.6%(3) PARIS, May 2, 2013 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2013 Change (reported) Change (CER) Net sales EUR8,059m -5.3% -2.8% Business net income(1) EUR1,613m -33.5% -28.8% Business EPS(1) EUR1.22 -33.3% -29.0% In order to facilitate an understanding of our...

2013-04-30 08:34:37

SANTA CLARA, Calif., April 30, 2013 /PRNewswire/ -- NextBio today announced a multi-year collaboration with Sanofi (NYSE:SNY) aimed at using NextBio Clinical to incorporate patient omics and clinical data into Sanofi's drug research and development, as part of Sanofi's Translational Medicine for Patients (TM4P) program. (Logo: http://photos.prnewswire.com/prnh/20130402/SF86976LOGO) NextBio will provide Sanofi with the NextBio Clinical platform for aggregation, standardization and analysis...

2013-04-30 08:33:46

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics(TM)--a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins--announced today that Henri A. Termeer, Genzyme's retired chairman, president, and CEO, has joined Moderna's board of directors. Over nearly 30 years at Genzyme, Termeer built one of the world's most innovative and commercially successful biotechnology...

2013-04-23 08:34:14

CHICAGO, April 23, 2013 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), and KaloBios Pharmaceuticals (Nasdaq: KBIO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an antibody fragment, intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa (Pa) in mechanically-ventilated patients. The Fast...